tagrisso
astrazeneca ab - osimertinib mesilate - karcinom, pljučni pljuč - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
zoladex 3,6 mg implantat v napolnjeni injekcijski brizgi
astrazeneca ab - goserelin - implantat - goserelin 3,6 mg / 1 brizga - goserelin
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastična sredstva - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
fasenra
astrazeneca ab - benralizumab - astma - zdravila za obstruktivne pljučne bolezni, - fasenra je indicirano kot dodatek na vzdrževanje zdravljenje pri odraslih bolnikih s hudo eozinofilno astmo neustrezno nadzorovano kljub visoki odmerki vdihavajo kortikosteroide plus dolgo delujoči beta agonistov.
lokelma
astrazeneca ab - natrijev cirkonij cyclosilicate - hiperkalemija - vsi drugi terapevtski izdelki - lokelma je primerna za zdravljenje hyperkalaemia pri odraslih bolnikih,.
calquence
astrazeneca ab - acalabrutinib - levkemija, limfocitna, kronična, b-celica - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
seroquel sr 150 mg tablete s podaljšanim sproščanjem
astrazeneca ab - kvetiapin - tableta s podaljšanim sproščanjem - kvetiapin 150 mg / 1 tableta - kvetiapin
symbicort turbuhaler 160 mikrogramov/4,5 mikrograma na odmerek prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 160 µg / 1 odmerek formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid
symbicort turbuhaler 80 mikrogramov/4,5 mikrograma na odmerek prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 80 µg / 1 odmerek formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid
symbicort turbuhaler 320 mikrogramov/9 mikrogramov na odmerek prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 320 µg / 1 odmerek formoterolijev fumarat dihidrat9 µg / 1 odmerek; formoterolijev fumarat dihidrat 9 µg / 1 odmerek - formoterol in budezonid